Pharmaceuticals News & Press Release Distribution

YolTech and KACTUS Join Forces to Propel Innovative DNA editing system in Greater China

Strategic Partnership to Advance Gene Editing Technologies in Biomedical Applications SHANGHAI, June 18, 2024 /PRNewswire/ -- YolTech, a clinical-stage biopharmaceutical company specializing in mRNA-LNP delivery forin vivo gene editing therapies, has partnered with KACTUS, a leading developer se...

2024-06-19 09:00 1678

Clover Announces Positive Preliminary Phase Ⅰ Results for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults

-- Bivalent SCB-1019 significantly boosted RSV-A and RSV-B neutralizing antibody titers in older adults up to approximately 7,900 IU/mL (up to 8-fold increase) and approximately 46,700 IU/mL (up to 11-fold increase), respectively -- -- Favorable safety & reactogenicity profile comparable to sali...

2024-06-18 17:41 2618

Diplomatic Envoys to China Visit Fosun: Appreciating Oriental Lifestyle Aesthetics and Seeking Opportunities for Business Cooperation

SHANGHAI, June 18, 2024 /PRNewswire/ -- Over 40 guests, including 10 ambassadors toChina, 8 consuls general and other senior diplomats from 26 countries, visited Fosun on 14 June. The delegation toured along the Grand Yuyuan. From the intangible cultural heritage of the Old City of Shanghai to t...

2024-06-18 12:53 3731

Live from EHA 2024 | Ascentage Pharma Releases Updated Data of Lisaftoclax in Patients with R/R MM and AL Amyloidosis Highlighting Marked Improvement in ORR

SUZHOU, China and ROCKVILLE, Md., June 18, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data of the Bcl-2 inh...

2024-06-18 12:43 2302

Live from EHA 2024 | Posters Featuring Results from Three Studies of Olverembatinib, Including Encouraging Data from US Study in CML and Ph+ ALL

SUZHOU, China and ROCKVILLE, Md., June 18, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that updated results from three studies of olverem...

2024-06-18 12:23 2083

Gan & Lee Pharmaceuticals to Present Groundbreaking Data on Three Innovative Products at the American Diabetes Association's 84th Scientific Sessions

* A phase 1b/2a trial evaluated once- and bi-weekly GZR18, a novel GLP-1 analog, in Chinese subjects with obesity/overweight * Pre-clinical studies evaluated the molecular and pharmacological properties of GZR4, an investigational once-weekly insulin analog * Pre-clinical studies evaluated ...

2024-06-18 12:13 2478

Gan & Lee Pharmaceuticals to Present Groundbreaking Data on Three Innovative Products at the American Diabetes Association's 84th Scientific Sessions

ReviR Therapeutics Reaches Milestone in Novel Splicing Therapy Development in Collaboration with Asieris Pharmaceuticals

BRISBANE, Calif. and SHANGHAI, June 17, 2024 /PRNewswire/ -- ReviR Therapeutics, a biotechnology company specializing in the development of small molecule RNA splicing modulators for neurogenetic diseases and oncology indications, and Asieris Pharmaceuticals, a global biopharmaceutical leader in ...

2024-06-17 22:00 1968

Leads Biolabs Unveils Preclinical Data on LBL-047, a Novel, First-In-Class Long-Acting TACI/Anti-BDCA2 Bispecific Antibody Fusion Protein in an Oral Presentation at EULAR 2024 Congress

NANJING, China, June 17, 2024 /PRNewswire/ -- At the recent European League Against Rheumatism (EULAR) Congress inVienna, Austria, Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) delivered an oral presentation on its highly innovative therapeutic candidate LBL-047. LBL-047 is a first-in-class, l...

2024-06-17 18:00 1319

Faculty of Medicine Siriraj Hospital and Dhulikhel Hospital commemorate 15 years of collaborative relationship

BANGKOK, June 17, 2024 /PRNewswire/ -- In 2024, Thai-Nepalese bilateral relations reached a new milestone as the Faculty of Medicine Siriraj Hospital at Mahidol University inThailand and Dhulikhel Hospital at Kathmandu University inNepal celebrated the 15th anniversary of their esteemed partnersh...

2024-06-17 15:04 1945

Faculty of Medicine Siriraj Hospital and Dhulikhel Hospital commemorate 15 years of collaborative relationship

IASO Bio Presented New Data of FUCASO® (Equecabtagene Autoleucel) for the Treatment of High-risk Newly Diagnosed Multiple Myeloma in Oral Presentation at EHA 2024

SHANGHAI and NANJING, China and SAN JOSE, Calif., June 15, 2024 /PRNewswire/ -- IASO biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, presented clinical data on the use of Equec...

2024-06-15 22:30 3905

CARsgen Presents First-in-human Results of GPRC5D Targeting CAR-T CT071 at EHA 2024

SHANGHAI, June 15, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the initial results from the ongoing first-in-human study of CT0...

2024-06-15 20:50 3442

Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)

* Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other thanChina and a few other areas. * Ascentage Pharma to receive an option payment of 100 million USD upon closing and be eligible for an option exercise fee and additional potential m...

2024-06-14 21:30 8688

Innovent Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer and Other Solid Tumors at the 2024 ESMO Virtual Plenary

SAN FRANCISCO and SUZHOU, China, June 14, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology ...

2024-06-14 08:34 5355

Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China

SAINT-CLOUD, France, June 13, 2024 /PRNewswire/ -- Ethypharm is pleased to announce the acquisition of a suppository form of Mesalazine by its Chinese affiliate, Shanghai Ethypharm Pharmaceuticals Ltd, from the Chinese Company Jiangsu Anbison Pharmaceutical. Leader in essential medicines for cen...

2024-06-13 22:33 2176

Sirnaomics Demonstrates Strong Antitumor Activity of Its Novel Oligonucleotide-ChemoDrug Conjugate in Journal of Oncology Research and Therapy

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 13, 2024 /PRNewswire/ -- Sirnaomics Ltd.(the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; stock code: 2257), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced that th...

2024-06-13 18:03 2915

Innovent Receives Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer

SAN FRANCISCO and SUZHOU, China, June 13, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...

2024-06-13 08:00 4288

Ansell Recognized with the Frost & Sullivan 2024 Global Company of the Year Award for Revolutionizing Workplace Safety and Promoting Sustainability

Ansell is committed to ensuring the safety and well-being of workers worldwide with an extensive range of safety solutions that meet the specific needs of clinicians and healthcare providers. SAN ANTONIO, June 12, 2024 /PRNewswire/ -- Frost & Sullivan recently researched and conducted a review o...

2024-06-12 21:00 1676

Latest Updates of Viva Biotech's Portfolio Companies

HONG KONG, June 12, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the suc...

2024-06-12 19:51 1928

Latest Updates of Viva Biotech's Portfolio Companies

HONG KONG, June 12, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the suc...

2024-06-12 19:51 2240

2024ASCO｜Memorial Sloan Kettering Cancer Center (MSK)'s Prof. Wungki Park Unveils Precision Targeting of TF in Pancreatic Cancer, Signaling ADC Drug Innovations

Introduction: ADC Drug Breakthrough Targets TF in Pancreatic Cancer CHICAGO, June 12, 2024 /PRNewswire/ -- The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, held inChicago from May 31 to June 4, shone a spotlight on MRG004A, a novel antibody-drug conjugate (ADC) designed to tr...

2024-06-12 19:31 1306